Epstein Secrets

head...Buy ACAD, AGN, ANTM, CELG, CVS, DHR, EW, EVHC, RARE, REGN, WBA Date: December 15, 2016 at 10:59:39 AM EST To: "Rich Kahn" Pd Reply-To: "Ens, Amanda" co The US team is out with their 2017 Year Ahead this morning ( top pick into the new year. ink) running through ALL sub-sectors with each analyst

n pockets) but pipelines/growth remains. Ying’s top picks are CELG & REGN; Tazeen’s top picks are ACAD & RARE. Spec Pharma (-) — headwinds remain w/ Sumant’s top pick AGN given lower risk to reimbursement pressures & an underappreciated pipeline. Leverage & CF remain the key focus for investors. Tools/A

50 - currently at 861.00 down 2.3% from purchase please advise thank you Richard Kahn HBRK Associates Inc. Begin forwarded message: From: "Ens, Amanda" Subject: Add to TEVA and AGN Date: August 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pricing

e loss on 2 of its 5 Copaxone patents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA, MYL & MNTA walking through his assumptions/thoughts. For TEVA, while today's ruling is somewhat of a setback, I'd argue that

rently at 861.00 down 2.3% from purchase please advise thank you Richard Kahn HBRK Associates Inc. tee= fa Begin forwarded message: From: "Ens, Amanda" < Subject: Add to TEVA and AGN Date: August 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pricin

e loss on 2 of its 5 Copaxone patents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA, MYL & MNTA walking through his assumptions/thoughts. For TEVA, while today's ruling is somewhat of a setback, • argue that

ard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York NY 10022 tel fax cell Begin forwarded message: EFTA00665656 From: "Ens, Amanda" < Subject: Add to TEVA and AGN Date: August 25, 2016 at 9:35:43 AM EDT To: Richard Kahn c > Rich, With yesterday's weakness in healthcare on pr

e loss on 2 of its 5 Copaxone patents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA, MYL & MNTA walking through his assumptions/thoughts. For TEVA, while today's ruling is somewhat of a setback, I'd argue that

eas Richard =ahn HBRK Associates Inc. 575 Lexington =venue 4th Floor New York, NY 10022 tel fax cel Begin forwarded message: From: =/b>"Ens, Amanda" Subject: =/b>US Healthcare =ear Ahead...Buy ACAD, AGN, ANTM, CELG, CVS, DHR, EW, EVHC, RARE, REGN, =BA Date: =/b>December 15, 2016 at 10:59:39 =M

) but pipelines/growth remains. Ying's top =icks are CELG =amp; REGN;=Tazeen's top picks are ACAD =amp; RARE. Spec Pharma (-) — =eadwinds remain w/ Sumant's top =ick AGN =iven lower risk to reimbursement pressures & an underappreciated =ipeline. =/span>Leverage & CF remain the key focus for investors.